❯ Science Corporation raises $400 million to expand PRIMA in Europe and prepare a US submission
Second large round this yearOn November 17, Science Corporation announced a $400 million Series D, bringing cumulative funding above $900 million. Participants included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital and Y Combinator. Science raised $230 million in March as it prepared to commercialize its PRIMA retinal implant system. The latest round supports expansion in Europe and US regulatory work.
From clinical study to European launchPRIMA pairs camera-equipped glasses with a retinal implant that converts images into stimulation signals for patients with certain forms of vision loss. A prior single-arm study of 38 participants reported gains in reading acuity for some patients. The device obtained a CE mark and began its European rollout in July. The company has started national reimbursement applications and site activation, which determine when patients can receive treatment and who pays.
The US regulatory pathThe FDA has granted humanitarian use device designations for two indications, and Science plans to apply for marketing authorization under the Humanitarian Device Exemption pathway. The round also supports research, manufacturing and operations. Europe is in commercialization while the US move remains at the preparation stage.
▮ SIGNALScience can fund European delivery and US regulatory work in parallel, with site activation and reimbursement determining how quickly clinical progress turns into revenue.